Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Page 9 of 9
Jan 11, 2026The infusion of $4.6 million in capital reflects growing investor confidence in artificial intelligence's potential to transform behavioral health care. Oasys Health aims to leverage this funding to develop technology solutions that better support mental health conditions through machine learning and personalized intervention.
Jan 10, 2026The funding enables Apella to accelerate development and deployment of its AI platform for hospitals. Its technology aims to optimize operating room scheduling and utilization, enhancing patient access and improving clinician work conditions.
Jan 6, 2026With the rise of telehealth services, providers are leveraging digital platforms to deliver the popular Wegovy pill, reflecting digital health’s role in expanding obesity treatment access.
Jan 6, 2026The FDA aims to encourage innovation and deployment of AI-enabled medical devices by reducing oversight, signaling a shift in regulatory approach toward digital health technology.
Jan 6, 2026The launch of the oral Wegovy pill has triggered a swift response from telehealth platforms aiming to capitalize on the growing obesity treatment market by expanding access to this convenient medication deployment option.
Jan 6, 2026With obesity continuing as a widespread health issue, telehealth companies are capitalizing on the convenience and accessibility of the newly approved oral Wegovy pill. The move reflects a growing trend of digital health platforms integrating pharmaceutical therapies for greater patient reach.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.